MetaVia Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MTVA research report →
Price Chart
About the company
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).
- CEO
- Hyung Heon Kim
- IPO
- 2016
- Employees
- 8
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on MTVA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.75M
- P/E
- -0.36
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.29
- EV/EBITDA
- 0.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -209.67%
- ROIC
- -213.33%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-19,000+20.8%
- Op Income
- $-13,708,000
- Net Income
- $-12,973,000+53.0%
- EPS
- $-7.35+81.2%
- OCF Growth
- +36.5%
- FCF Growth
- +36.5%
- 52W High
- $14.85
- 52W Low
- $0.97
- 50D MA
- $1.58
- 200D MA
- $2.36
- Beta
- 0.96
- RSI (14)
- 37
- Avg Volume
- 234.13K
No earnings-call transcripts are available for MTVA yet.
- Free Float
- 72.8%
- Shares Outstanding
- 6.59M
- Float Shares
- 4.80M
of shares held by institutions
12 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jane Street Group, LLC | 123.58K | ▲ 112.68K |
| Citadel Advisors LLC | 61.21K | ▲ 61.21K |
| Virtu Financial LLC | 29.93K | ▲ 29.93K |
| Geode Capital Management, LLC | 21.31K | ▼ 12.32K |
| Vanguard Group Inc | 20.09K | ▲ 20.09K |
| Ubs Group AG | 12.95K | ▲ 12.95K |
| Scientech Research LLC | 12.01K | ▲ 12.01K |
| Aries Wealth Management | 10.00K | 0 |
| Vanguard Capital Management LLC | 8.92K | ▲ 6.70K |
| Vanguard Fiduciary Trust Co | 6.94K | 0 |
| Tower Research Capital LLC (Trc) | 2.22K | ▼ 379 |
| Sbi Securities Co., Ltd. | 270 | ▲ 65 |
Held by 4 ETFs
Biggest fund positions in MTVA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 8, 26 | Tursi James Patrick | other | 17,186 |
| Jun 8, 26 | STRICKLAND D GORDON | other | 17,186 |
| Jun 8, 26 | Salsbury Michael | other | 17,186 |
| Jun 8, 26 | GROVES JASON L | other | 17,186 |
| Jun 8, 26 | KOVEN ANDREW I | other | 17,186 |
| Jun 8, 26 | Glickman Mark A | other | 17,186 |
| Jan 23, 26 | Woodworth Marshall H | other | 28,000 |
| Jan 23, 26 | Kim Hyung Heon | other | 32,000 |
| Aug 12, 25 | Woodworth Marshall H | other | 14,200 |
| Jun 30, 25 | Glickman Mark A | other | 28,147 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MTVA coverage
Recent articles, reports, and earnings notes.
No research on MTVA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MTVA report →MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
prnewswire.com · Sep 9
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
prnewswire.com · Aug 6
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
prnewswire.com · Jul 9
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
prnewswire.com · Jun 17
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
globenewswire.com · Jun 9
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
prnewswire.com · Jun 8
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
prnewswire.com · Jun 4
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
prnewswire.com · May 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.